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ABSTRACT 24 
Cadherins are mediators of cell-cell adhesion in epithelial tissues. E-cadherin is a known tumour suppressor and 25 
plays a central role in suppressing the invasive phenotype of cancer cells. However, the abnormal expression of N- 26 
and P-cadherin (“cadherin switching”) has been shown to promote a more invasive and malignant phenotype of 27 
cancer, with P-cadherin possibly acting as a key mediator of invasion and metastasis in bladder cancer. Cadherins are 28 
also implicated in numerous signalling events related to embryonic development, tissue morphogenesis, and 29 
homeostasis. It is these wide-ranging effects and the serious implications of cadherin switching that make the 30 
cadherin cell adhesion molecules and their related pathways strong candidate targets for the inhibition of cancer 31 
progression, including bladder cancer. This review will focus on cadherin switching in the context of bladder cancer 32 
and in particular the switch to P-cadherin expression, and will discuss other related molecules and phenomena, 33 
including EpCAM and the development of the cancer stem cell phenotype. 34 
 35 
MEDIA SUMMARY 36 
 Cadherins are mediators of cell-cell adhesion in epithelial tissues. E-cadherin is a tumour suppressor and plays a 37 
central role in suppressing the invasive phenotype of cancer cells. However, the abnormal expression of other 38 
cadherins (“cadherin switching”) has been shown to promote a more invasive and malignant phenotype of cancer. 39 
Cadherins are also implicated in numerous signalling events related to embryonic development, tissue 40 
morphogenesis, and homeostasis. It is these wide-ranging effects and the serious implications of cadherin switching 41 
that make the cadherin cell adhesion molecules and related pathways attractive targets for the inhibition of cancer 42 
progression, including bladder cancer.43 
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BLADDER CANCER 44 
Introduction 45 
Urothelial bladder cancer (UBC) is the fifth most common cancer in Western society, with a global incidence of over 46 
356,000 and a prevalence estimated at 2.7milion [1;2]. The burden of the disease is predicted to increase 47 
significantly in the foreseeable future as a result of population aging and the increasing world population, together 48 
with the progression of the tobacco epidemic and increasing exposure to occupational carcinogens in developing 49 
countries [2]. In the UK there are approximately 10,200 new cases and 5,000 deaths attributed to bladder cancer per 50 
year [3]. In Western populations over 90% of bladder cancers are transitional cell carcinomas of urothelial origin 51 
(urothelial cancers, UCs), and at presentation 75-85% will be non-muscle-invasive tumours (NMIBC, stages 52 
Ta/T1/Tis), with the remainder being muscle-invasive (MIBC, stages T2-4) [1;4-6]. 53 
NMIBC is a heterogeneous disease typified by a high rate of recurrence (15-61% at one year, depending upon risk 54 
category [7]) and so long-term, even lifelong, surveillance with outpatient flexible cystoscopy is the mainstay of 55 
subsequent management [6;8]. Progression to MIBC is also a concern for high-risk NMIBC patients, occurring in up to 56 
17% of patients at one year [7]. However, the overall prognosis is good with 65-85% of patients surviving for 5 years 57 
or more [5].  58 
Progression to (or presentation with) MIBC represents the critical step in the disease course, necessitating more 59 
radical therapies and carrying a 5-year survival rate of only 25-50% [5;9]. For curative intent, patients who present 60 
with or progress to MIBC are treated by radiotherapy [6;10], chemoradiotherapy [11], radical cystectomy, or 61 
neoadjuvant chemotherapy followed by radical cystectomy [6;9;10].  62 
The cumulative cost of treating UBC exceeds all other forms of human cancer, the majority of which is attributable to 63 
the long-term treatment and surveillance of NMIBC [12-14]. Despite this, there is only modest research funding for 64 
UBC compared to other malignancies [15], and as a result there has been a lack of scientific advancement in the field 65 
[15-17], with no major new drugs approved for UBC in over 10-years [17;18].  66 
Cadherins are mediators of cell-cell adhesion in epithelial tissues [19;20]. We have previously demonstrated that the 67 
abnormal expression of P-cadherin (an example of “cadherin swithching”) is associated with an invasive and 68 
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aggressive phenotype of UBC [21], and have hypothesized that P-cadherin may act as a key effector of muscle-69 
invasion [22]. The cadherins are involved in a number of important phenomena related to cancer progression, 70 
including epithelial-to-mesenchymal transition (EMT) and the development of a cancer stem cell phenotype [22;23]. 71 
It is these wide-ranging effects and the serious implications of cadherin switching that make the cadherins and their 72 
related pathways strong candidate targets for the inhibition of cancer progression, including UBC. This review will 73 
focus on cadherin-based cell adhesion in the context of UBC and the switch to P-cadherin expression, and will discuss 74 
other related molecules and phenomena, including EpCAM and the development of the cancer stem cell phenotype.  75 
 76 
METHODS 77 
Our group has been working in the field of cadherin biology for a number of years [24;25], and we regularly review 78 
the literature on these molecules and their associated pathways [22]. Specifically, this review was written utilising 79 
papers obtained following PubMed searches and with the following structure: bladder cancer background, 80 
epidemiology and molecular pathogenesis; cadherin background and biology; cadherins in epithelial malignancies, 81 
cadherin switching, and cadherins in bladder cancer. The background to cadherins and cadherin biology presented 82 
here has been derived from key papers by workers who initially characterised and described these molecules, and 83 
then who subsequently investigated cadherin expression and function in various epithelial malignancies and model 84 
systems. We updated the field for cadherin switching to describe this process in the context of malignancy and 85 
related phenomena (eg. epithelial-to-mesenchymal transition, cell migration, metastasis, cancer stem cells, EpCAM 86 
signalling), utilising papers written by significant workers in this field. The data, findings and information contained 87 
within these publications were then assimilated to create a review of cadherin switching in bladder cancer and 88 
including some of our own interpretations.  89 
 90 
MOLECULAR PATHWAYS TO NON-MUSCLE-INVASIVE & MUSCLE-INVASIVE BLADDER CANCER 91 
Different approaches have been taken to describe the molecular alterations involved in bladder tumorigenesis [26-92 
31]. We have previously described such pathways based upon the six “hallmarks of cancer” described by Hanahan 93 
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and Weinberg in 2000 [32-35]. In 2011 Hanahan and Weinberg updated their original landmark review, describing 94 
genome instability and inflammation as underlying these hallmark changes, and proposed “reprogramming of 95 
energy metabolism” and “evading immune destruction” as two emerging hallmarks with potential for generality 96 
[35]. In addition, they described that tumors exhibit another dimension of complexity by containing a repertoire of 97 
recruited, ostensibly normal cells that contribute to the acquisition of hallmark traits by creating the "tumor 98 
microenvironment" [35], and our own research has demonstrated the apparent importance of the immunological 99 
milieu of the bladder tumour microenvironment [RT Bryan et al - unpublished data]. In their 2011 update, Hanahan 100 
and Weinberg also introduced the concept of “cancer stem cells” [35], a concept that has existed for a number of 101 
years in haematopoietic malignancies [36;37]. Cancer stem cells (CSCs) are a subset of tumor cells that have the 102 
ability to self-renew and to generate all of the heterogeneous cells that comprise a tumor (properties that are 103 
analogous to a stem cell, the original cell of an organ and responsible for organogenesis and organ maintenance) 104 
[23;36;38-40]. In the setting of UBC, CSCs appear to play a role in a subset of tumors, but their true significance is yet 105 
to be clarified [23].  106 
Other authors have reviewed the field of UBC molecular pathogenesis in detail [26-31], and there has been general 107 
consensus on a divergent pathway for the development of Ta/T1 disease and Tis/T2+ disease [29;41-46]. However, 108 
Dancik et al recently identified a cell of origin gene signature for basal cells and umbrella cells of the urothelium [47]. 109 
By utilising this cell of origin signature in UBCs from 874 patients, it appeared that NMIBCs and MIBCs developed 110 
from distinct progenitor cells [47], possibly shifting our understanding of urothelial carcinogenesis away from the 111 
classical two pathway model. Further detailed genomic and epigenomic studies of both MIBCs and NMIBCs are thus 112 
required to clarify our understanding of the pathogenesis of these tumours [48].  113 
Although a detailed examination of these pathways is beyond the scope of this review, this is a rapidly changing field 114 
and new developments appear frequently with the advent of high-throughput experimental platforms including 115 
“deep sequencing” [49], proteomics [50-52] and metabolomics [53]. Most recently, The Cancer Genome Atlas (TCGA) 116 
Research Network undertook the comprehensive molecular characterization of 131 MIBCs [49]. With regard to 117 
somatic DNA mutations, a notable finding was the significant enrichment of non-silent mutations in chromatin 118 
regulatory genes compared to other epithelial cancers studied: 76% of the tumours (MIBCs) had an inactivating 119 
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mutation in one or more of these genes, and 41% had at least two such mutations [49]. TP53 mutations were also 120 
common (49%), as were amplification and overexpression of MDM2, suggesting that TP53 function was inactivated 121 
in 76% of tumours [49]. There were a large number of previously undescribed mutations, and viral DNAs and 122 
transcripts were also indentified [49]. RNA-seq data identified 4 tumour clusters and pathway analysis demonstrated 123 
three frequently dysregulated pathways [49]: cell-cycle regulation (altered in 93% of cases); kinase and 124 
phosphatidylinositol-3-OH kinase (PI(3)K) signaling (72%); and chromatin remodelling (89%). A number of the 125 
genomic alterations indentified are theoretically amenable to therapeutic targeting [49], and such new therapeutics 126 
are desperately needed for UBC [17;18;54].  127 
Choi et al also utilised whole genome mRNA expression profiling to cluster MIBCs into 3 distinct groups, based upon 128 
the established molecular subtypes of breast cancer [55]: basal MIBCs shared biomarkers with basal breast cancers 129 
and were characterized by p63 activation, squamous differentiation, and more aggressive disease; luminal MIBCs 130 
contained features of active PPARγ and oestrogen receptor transcription and were enriched with activating FGFR3 131 
mutations and potential FGFR inhibitor sensitivity; p53-like MIBCs were consistently resistant to a number of 132 
chemotherapeutics, including cisplatin; and all chemoresistant tumours adopted a p53-like phenotype after therapy 133 
[55]. These findings have important implications for the clinical management of MIBC: they include not only 134 
prognostic information, but also suggestions for subtype-directed targeted therapy and potential to predict response 135 
to cisplatin-based chemotherapy (although further work is needed to elucidate other biomarkers of resistance) [56]. 136 
It is, however, disappointing that NMIBCs were not analysed in the same way by either the TCGA Research Network 137 
or Choi et al [48], especially as these tumours represent the vast majority (>75%) of bladder cancer patients [57;58].  138 
 139 
CADHERINS 140 
The classical cadherins are calcium-dependent transmembrane glycoproteins found at the adherens junction and are 141 
mediators of cell-cell adhesion in epithelial tissues [19;20]. E-cadherin is a tumour suppressor, playing a central role 142 
in suppressing the invasive phenotype of UBC cells [59]. The abnormal expression of other “classical” cadherins (P- 143 
and N-cadherin) has been shown to promote a more invasive and malignant phenotype of UBC [24], possibly acting 144 
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as key mediators of invasion and metastasis. With such a large difference in UBC outcomes between early stage 145 
disease (stage Ta) versus MIBC (stages T2+) it is reasonable to assume that cell adhesion molecules, and in particular 146 
cadherins, play a fundamental role in the spread of bladder tumours, initially from the urothelium into the lamina 147 
propria (through the basement membrane) and subsequently into the detrusor muscle [22]. Therefore, the classical 148 
cadherins and their related molecular pathways represent attractive therapeutic targets for the inhibition of 149 
progression in bladder cancer patients [19;59-61]. 150 
Cadherins comprise of extracellular (EC1-5), transmembranous, and cytoplasmic domains, with the cytoplasmic 151 
domain anchored to the cell cytoskeleton by catenin family members (α-, β-, γ-catenin and p120) [19;61-65]. P21-152 
activated kinase 5 (PAK5) also appears to associate with β-catenin and p120 to stabilise the adherens junction in 153 
order to maintain normal cell-cell adhesion [66]. Traditionally, cell-cell adhesion is described as being achieved by 154 
the symmetric interactions of the first extracellular domains (EC1) of cadherins on neighbouring cells (trans-155 
interaction) [64;67]; cadherins on the same cell also interact with each other (cis-interaction) through the EC1 156 
domain of one and the EC2 domain of the other [64;67;68]. More recently, it has been described that optimal cell-157 
cell adhesion (50-70pN) is achieved by all 5 EC domains of E-cadherin, and with a cell-cell separation of 5-11nm [65]. 158 
See Figure 1. E-, P- and N-cadherin were the first cadherins identified, and can all mediate cell-cell adhesion in this 159 
fashion [63;69]: 160 
• E-cadherin (CDH1, 120kDa): the main mediator of cell-cell adhesion in epithelial tissues and expressed by 161 
most normal epithelial cells [19;61;62;69-71].  162 
• N-cadherin (CDH2, 130kDa): expressed by neural, endothelial, and muscle cells, but not normally by 163 
epithelial cells [62;69].  164 
• P-cadherin (CDH3, 118kDa): normally only weakly expressed in the basal layers of stratified epithelia such as 165 
oesophagus, bronchus and bladder [24;69;71].  166 
Epithelial malignancies, including bladder cancer, typically show loss of E-cadherin expression as grade and stage 167 
progress, and this is often accompanied by increased expression of N- or P-cadherin. This phenomenon is described 168 
as “cadherin switching” [19;61;69;71-73], illustrated in the bladder cancer setting in Figure 2. Excellent reviews of 169 
 RT Bryan  8 
 
the field have been published recently [74;75], and we have previously reviewed this field for bladder cancer [22]; 170 
we provide an overview below. 171 
 172 
CADHERIN SWITCHING 173 
Cadherin switching (CS) is a hallmark of epithelial-to-mesenchymal transition (EMT) [76], the process by which 174 
epithelial cells lose their characteristic polarity, disassemble cell junctions, and become more migratory as a 175 
precursor to invasion and metastasis (they acquire properties analagous to mesenchymal cells) [19;25;61;77-82]. In 176 
this setting, CS typically describes a process where the normal expression of E-cadherin is replaced by the abnormal 177 
expression of N-cadherin, or where N-cadherin expression is increased and E-cadherin levels remain unchanged 178 
[19;61;76]. CS appears to play a role late in many malignancies (including breast, prostate, pancreas, ovarian, 179 
bladder and melanoma), resulting in a more invasive and malignant phenotype of disease with a worse outcome 180 
[19;24;61;74-76;83-89]. The regulation of CS is yet to be fully elucidated, but most likely involves transcriptional and 181 
post-transcriptional events, possibly influenced by cytokines or growth factors [19;61]. Recently, Slug (SNAI2, a 182 
member of the Snail family of zinc-finger transcription factors) has been identified to play a critical role in EMT by 183 
control of the E-cadherin to N-cadherin switch in UBC [90]. 184 
In UBC, ourselves and others have described CS, demonstrating increased expression of both P- and N-cadherin in 185 
late stage high-grade disease (Figure 2) [24;69;89;91;92]. We studied 153 bladder tumours and utilised a variety of 186 
cell lines and functional in vitro models [24]: increased membranous P-cadherin expression was observed in almost 187 
half of all MIBCs and almost 40% of grade 3 UBCs, accompanied by significantly reduced expression of E-cadherin 188 
[24]. Increased P-cadherin expression was associated with worse bladder cancer-specific survival, and P-cadherin 189 
status was an independent prognostic factor (alongside grade and stage) [24]. Functional in vitro experiments 190 
showed that altering the balance of E- and P-cadherin in favour of P-cadherin expression enhanced anchorage-191 
independent growth, and that P-cadherin alone was unable to mediate normal cell-cell adhesion [24]. We concluded 192 
that P-cadherin expression promoted a more malignant and invasive phenotype of bladder cancer (even in the 193 
presence of E-cadherin), and appeared to have a novel role late in the disease process [24].  194 
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Mandeville et al also demonstrated similar findings [92]. In their in vitro studies, utilising P-cadherin transfection and 195 
knockdown, they demonstrated that P-cadherin induced a significant increase in migratory capacity (although with 196 
no accompanying change in invasive potential) [92]. The authors suggested that P-cadherin may have a role in 197 
regulating the migration of basal cells to the intermediate cell layer in normal urothelium, as well as a role in 198 
neoplastic progression [92].  More recently, Wang et al have demonstrated similar findings [89].  199 
Ourselves and others have postulated that a subgroup of aggressive P-cadherin-expressing tumours may be derived 200 
from the normally weakly P-cadherin-expressing basal layer of the urothelium [22]. In support of this hypothesis, 201 
Van Batavia et al recently demonstrated that papillary and CIS lesions were derived from different urothelial 202 
populations, with intermediate cells contributing to non-invasive papillary lesions and basal cells representing the 203 
origin of CIS (which ultimately leads to MIBC) [93]. These findings support a model in which the heterogeneity 204 
observed in bladder cancers is determined both by genetic changes and the cell lineage from which the tumour 205 
originates [93].   206 
However, despite P-cadherin expression being associated with a more aggressive phenotype in many cancers, such 207 
behaviour is not ubiquitous and is context dependent [75]. For example, in malignant melanoma, which commonly 208 
demonstrates a cadherin switch to N-cadherin expression [22], P-cadherin promotes adhesion and inhibits invasion 209 
in a similar fashion to E-cadherin [75], and E-cadherin negative breast cancer cells show many similarities when 210 
subsequently transfected with E- or P-cadherin [74;94]. Ribeiro et al investigated these phenomena in detail in a 211 
breast cancer model, demonstrating that P-cadherin co-localizes with E-cadherin, and promotes cell invasion by 212 
disrupting E-cadherin/catenin interactions [95]. E- and P-cadherin co-expressing tumour cells showed enhanced in 213 
vivo tumour growth compared with those expressing only E- or only P-cadherin, and co-expression of E- and P-214 
cadherin in breast tumours correlated with high-grade biologically aggressive tumours accompanied by poor patient 215 
survival [95]. It is therefore feasible that P-cadherin only promotes invasion in tissues that endogenously express E-216 
cadherin [74], with heterodimerisation between E- and P-cadherin disrupting the formation of functional cadherin-217 
catenin complexes [75]. 218 
It is likely that the key mechanisms involved in P-cadherin’s deregulation largely occur in the promoter region of 219 
CDH3 and not by structural alterations of its coding sequences [74]: in 2005, Paredes at al demonstrated 220 
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hypomethylation of the CDH3 gene promoter correlated with P-cadherin overexpression in breast cancer [74;96], 221 
and other workers have described this phenomenon in pancreatic [74;97] and colorectal cancers [74;98]. Our own 222 
data suggest differential CDH3 promoter methylation between bladder cancer cell lines and tumours, and normal 223 
urothelium [RT Bryan - unpublished data]. Furthermore, the balance of E- and P-cadherin expression impacts the 224 
overall genetic programme [74], altering the expression of genes involved in signal transduction and growth factors, 225 
cell cycle, cell adhesion and the extracellular matrix, cytokines and inflammation [74;94]. In addition, P-cadherin can 226 
provoke the secretion of pro-invasive factors such as the matrix metalloproteinases MMP1 and MMP2 [74;75;99]. 227 
The role of p120 also appears important, with P-cadherin probably interfering with the normal binding of p120 to E-228 
cadherin at the adherens junction [74;100]. In a pancreatic cancer model, accumulation of p120 in the cytoplasm 229 
(and not bound to E-cadherin at the membrane) appeared to induce the increased cell migration seen following P-230 
cadherin expression via the Rho GTPases, Rac1 and Cdc42 [74;101]. P-cadherin-induced increase in Rac1 and Cdc42 231 
activity (mediated via p120) has also been observed in ovarian cancer [74;102]. Specifically, insulin-like growth factor 232 
1 receptor (IGF1R) can seemingly form a complex with P-cadherin, resulting in the tyrosine phosphorylation and 233 
activation of cytoplasmic p120 to promote invasion [75;102;103]; this pathway appears specific to P-cadherin and 234 
not the other classical cadherins [75;103].  235 
Taken together, all of the data above emphasise that P-cadherin represents a very attractive target for novel anti-236 
cancer therapeutics [74], and phase I trials of a P-cadherin inhibitor (PF-03732010, a human monoclonal antibody 237 
against P-cadherin) have been undertaken [104], although its development now seems to have stalled.  238 
 239 
CADHERINS AND CANCER STEM CELLS 240 
Although solid tumours can be reduced in size or eradicated by chemotherapy, radiotherapy or surgery (alone or in 241 
combinations), disease relapse or progression often occurs [105;106]. Such relapse or progression may be explained 242 
by the persistence of residual tumour-initiating cells and tumour-maintaining cells, and such cells have been 243 
reported in a variety of malignancies (breast, brain, prostate, lung, pancreas, etc) since they were first identified in 244 
leukaemia [79;105;107]. Such “cancer stem cells” (CSCs) theoretically have the ability to self-renew and to generate 245 
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the heterogeneous cells that comprise a tumour [105-110], and thus need to be eradicated to provide long-term 246 
disease-free survival (although it appears that CSCs are more resistant to conventional therapies) [108;110-112]. 247 
CSCs may either develop following genetic or epigenetic events in normal stem cells or from differentiated tumour 248 
cells that develop the capability for unlimited growth [23;82]. Cellular markers of “stemness” are still under debate, 249 
but include CD44, CD24, CD133 and EpCAM [82]: in breast, prostate and oral squamous carcinomas, CSCs are likely 250 
identified as CD44+/CD24-, whereas CD133 appears to be a CSC marker in gliomas and in colon and pancreatic 251 
carcinomas [82]. 252 
In a previous review we suggested that the evidence supports the CSC paradigm for UBC, as in other epithelial 253 
malignancies [23]. As discussed above, in normal urothelium P-cadherin is only expressed in the basal cell layer (the 254 
assumed urothelial stem cell niche) and in a subset of more aggressive UBCs [21-23;92;113]. It is therefore tempting 255 
to assume that P-cadherin is a marker of urothelial stem cells and UBC CSCs. Although E-cadherin intercellular 256 
adhesion is considered important for the survival of human embryonic stem cells (hESCs) and induced pluripotent 257 
stem cells (iPSCs) [82], Kolle et al recently identified CDH3 (P-cadherin) and TACSTD1 (EpCAM) as genes encoding 258 
hESC markers (antibodies for EpCAM were also able to enrich for pluripotent hESCs) [114]. Vieira et al have also 259 
demonstrated that P-cadherin mediates stem cell properties in basal-like breast cancer [115]. P-cadherin therefore 260 
appears promising as a potential marker of CSCs in UBC, and similar work is required to confirm these findings in 261 
UBC [23]. The fact that CDH3 (P-cadherin) did not appear in Dancik et al’s cell of origin signature described earlier is 262 
somewhat surprising since it is normally expressed by basal urothelial cells and in a subset of aggressive UBCs that 263 
may also harbour CSCs; however, as described above, P-cadherin’s deregulation is most likely governed by 264 
epigenetic phenomena rather than structural alterations in its coding sequences [74]. Characterisation of the UBC 265 
epigenome/methylome may thus be required to elucidate P-cadherin’s role in these UBC subtypes. 266 
It is highly feasible that treatment-resistant cells develop via other mechanisms and pathways, with CSCs being 267 
responsible only for a minority [105;116]. Heterogeneity within some tumours may result from selective pressure 268 
during tumorigenesis [35;112]. See Figure 3. It has been suggested that UBCs arise from more differentiated cells, 269 
and self-renewal capacity may be acquired secondarily by inactivation of p53 and RB1 function [105;116]. The 270 
tumour microenvironment may also play an important role [108], potentially inducing a transitory or reversible CSC-271 
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like state [117]: although EMT may drive the development of CSCs [35], EMT itself is reversible with mesenchymal-272 
to-epithelial transition (MET) favouring a cell’s colonisation of distant sites to generate metastases [35]. Whether the 273 
CSC state reverses in a similar setting and fashion remains unknown, but such interactions highlight the importance 274 
of the tumour microenvironment for all cancer cells, not just CSCs [35]. 275 
 276 
CADHERINS AND EPCAM 277 
EpCAM is a type-1 membrane protein that functions as a cell adhesion molecule [118]. It is overexpressed in many 278 
epithelial malignancies, including bladder CIS [119] and high grade and advanced stage UBCs [120]. The tumour-279 
specific expression of EpCAM has led to its use for capturing circulating tumour cells by the FDA-approved 280 
CELLSEARCH system [121], and also for directing therapies to bladder tumours [122]. High tissue levels of EpCAM are 281 
associated with a poor prognosis in UBC [120]. However, the role of EpCAM remains elusive: both tumour 282 
suppressor and oncogenic properties have been reported. In 2009, Maetzel et al demonstrated that EpCAM could be 283 
sequentially cleaved to release extracellular and intracellular domains, ‘EpEX’ and ‘EpICD’, respectively [123]; EpICD 284 
diffuses into the nucleus and activates oncogenic signalling events by associating with FHL2, β-catenin and Lef-1 285 
[123;124]. See Figure 4. 286 
In 2014, as part of our de novo urinary biomarker discovery programme [125], we demonstrated that elevated 287 
urinary EpCAM was observed in patients with grade 3 NMIBCs and MIBCs [51;52]. EpCAM was a significant 288 
independent prognostic factor for UBC-specific survival, with elevated urinary levels resulting in an increased risk of 289 
dying from bladder cancer (hazard ratio 1.76). The predominant form of EpCAM in the urine was a soluble and stable 290 
form comprised of the entire extracellular domain, and not the intact protein [52]. Our data therefore suggested 291 
that the cleavage of EpCAM into EpEX and EpICD could also occur in UBC [52;123], and further evidence supports 292 
this: Ralhan et al recently demonstrated that 9 out of 10 cases of UBC were positive for EpICD [126]. However, our 293 
work demonstrated that the extracellular domain of EpCAM was released by cleavage immediately adjacent to the 294 
cell membrane [52]; the exact location of cleavage was not described by Maetzel et al [123], but the protease 295 
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involved (TACE or ADAM 17) usually cleaves membrane proteins 10-15 residues away from the membrane surface 296 
[127], suggesting atypical cleavage or an alternative mechanism of extracellular domain release in UBC [52].  297 
Notably, there are important relationships between EpCAM and classical cadherins, although this relationship 298 
appears to be tissue- and tumour-specific [128]. In 1997, Litvinov et al suggested that EpCAM has a role in the 299 
development of a proliferative and malignant phenotype of epithelial cell [129]: increasing the expression of EpCAM 300 
in cadherin-positive cells led to the gradual abrogation of adherens junctions [129]. Although EpCAM had no 301 
influence on the total amount of cellular cadherin, it affected the interaction of the cadherins with the cytoskeleton 302 
and, as cadherin-mediated cell-cell adhesion diminished, EpCAM-mediated intercellular connections predominated 303 
[129]. In a murine fibroblast model, Winter et al subsequently demonstrated that this may occur by disruption of the 304 
link between α-catenin and F-actin, probably by EpCAM’s disruption of the actin cytoskeleton or possibly via p120 305 
[130]. In later work on human breast epithelial cells, the same authors demonstrated that EpCAM cross-signaling 306 
with N-cadherin resulted in the abrogation of cadherin adhesion complexes, mediated by PI(3)K [131]. In breast 307 
cancer cell lines, Martowicz et al showed that epithelial cells need EpCAM to promote growth and invasion, yet 308 
mesenchymal tumour cells are independent of EpCAM for invasion and progression [132]; the same authors also 309 
demonstrated that overexpression of EpCAM in human mammary epithelial cells led to a more proliferative 310 
phenotype and downregulation of E-cadherin [133]. 311 
Conversely, in a zebrafish model, Slanchev et al demonstrated that EpCAM was indispensible for skin epithelial 312 
integrity, and that epcam mutant embryos displayed reduced levels of membranous E-cadherin [134]. Guerra et al 313 
also postulated an important role for EpCAM in the maintenance of normal intestinal architecture and function in 314 
congenital tufting enteropathy, utilising an mTrop1/Epcam knockout mouse model of the disease [135]. Other model 315 
systems have also demonstrated a direct association between loss of EpCAM expression and loss of cadherin-316 
mediated adhesion [136]. 317 
Seemingly, EpCAM has dual functions in normal and cancerous cells with regard to cadherin regulation, cell-cell 318 
adhesion and epithelial integrity: EpCAM may be essential for normal epithelial tissue integrity and cell-cell 319 
adhesion, but there also appears to be a role for EpCAM in the disruption of normal cell-cell adhesion to initiate 320 
EMT, with the subsequent transformed cells acting independently of EpCAM signaling for invasion and progression. 321 
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Interestingly, Zeb1 (a known transcription factor inducing EMT) represses both E-cadherin and EpCAM by binding to 322 
the EpCAM promoter [137], yet the expression of E-cadherin and EpCAM is related to a stem cell-like phenotype 323 
[138;139]; in basal-like breast cancer EpCAM and P-cadherin both appear to be associated with the CSC phenotype 324 
[115]. As described for the hallmarks of cancer [34], the timing and ordering of these events appears to differ 325 
between normal and tumerous tissues, between different tissue and tumour types, and most likely within the same 326 
tumour. It is feasible that during EMT in some malignancies, EpCAM may stimulate the dissolution of E-327 
cadherin/catenin complexes and so permit P- and N-cadherin complexes to predominate (cadherin switching) and β-328 
catenin-mediated oncogene transcription to be upregulated; yet in other tumour types, EpCAM and E-cadherin may 329 
be downregulated in parallel, with EMT being driven by alternate pathways. Conversely, EpCAM may stabilise E-330 
cadherin/catenin complexes in some tumours, possibly providing a "stable" and less chaotic cellular milieu 331 
unaffected by EMT, in which the development of a CSC phenotype can be "nurtured" by alternative pathways (as 332 
described above, EpCAM is a cell surface marker of hESCs, and can be used to isolate a pluripotent subpopulation 333 
from hESC culture [114]). If the latter model is correct, then the corollary would potentially be the normalisation of 334 
β-catenin-mediated transcription in CSCs; evidence to date in other malignancies suggests that this is not the case 335 
[140-142]. However, these are dynamic processes, and even within the same tumour all of these proposed 336 
phenomena may be unfolding simultaneously; in the future, single cell genomics may resolve these issues [143;144]. 337 
It is important to note that CSC-like treatment-resistant disease may develop via alternate pathways (Figure 3), and 338 
there is likely to be considerable plasticity [142], with cells reverting to a less aggressive state by mesenchymal-to-339 
epithelial transition (MET) or by the reversal of the CSC phenotype. Furthermore, the influence of EpCAM on P-340 
cadherin is yet to be elucidated. Our current research is attempting to resolve some of these mechanisms. 341 
 342 
343 
 RT Bryan  15 
 
DISCUSSION & CONCLUSION 344 
P-cadherin seemingly has a number of fundamental roles in bladder cancer and other malignancies, including 345 
mediating the development of CSCs and EMT, both of which lead to more aggressive disease and worse survival. The 346 
mechanisms of these phenomena have been well-described in other malignancies, but remain to be elucidated in 347 
UBC. Although we have assumed some crossover of P-cadherin’s function between tumour and tissue types, we 348 
know that many of P-cadherin’s actions are tumour- and tissue-specific. Therefore, such findings from other 349 
malignancies need to be reproduced in UBC if we are to genuinely understand P-cadherin’s role in this setting. 350 
However, given the genomic characterizations of MIBC described above [47;49;55], it is unlikley that P-cadherin 351 
represents a “driver” of urothelial carcinogenesis [145]; P-cadherin is more likely to represent an important 352 
downstream effector of such driver mutations, with multiple influences on important pathways and phenomena that 353 
determine outcomes in advanced disease (eg. EMT, CSCs), probably mediated by PI(3)K [49]. Moreover, it appears 354 
that P-cadherin plays a fundamental role in the cell surface and cell adhesion phenomena that permit tumour cells 355 
to migrate and invade, and possibly to metastasize. 356 
In conclusion, P-cadherin represents a highly attractive therapeutic target, alongside N-cadherin [146-148]. However, 357 
given P-cadherin’s complex interactions described above (and undoubtedly many yet to be discovered), P-cadherin 358 
inhibition may have far more wide-reaching effects than those directly related to tumour invasion and progression. 359 
The difficulties of taking an anti-P-cadherin agent through clinical trials and into clinical use should therefore not be 360 
underestimated. Furthermore, the association of classical cadherins with EpCAM is particularly fascinating and 361 
requires further elucidation in UBC, and our work in this area is ongoing.  362 
363 
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LEGENDS FOR FIGURES 706 
Figure 1: Cell-cell adhesion in epithelial tissues (taken from [22]). a) overview of cell-cell adhesion complexes; b) 707 
pictorial representation of cell-cell interactions on neighbouring cells; c) molecular structure of the adherens 708 
junction, showing the relationship between E-cadherin molecules on neighbouring cells, and between E-cadherin, 709 
the catenins (α, β, γ, p120) and the cell cytoskeleton. Traditionally, cadherins on neighbouring cells adhere via EC1 710 
domains, although more recent research suggests that all 5 EC domains are required for optimal adhesion [65].  711 
Figure 2: Cadherin switching in bladder UCs (taken from [22]). a) E-cadherin is strongly expressed at the cell 712 
membrane throughout the normal urothelium. Reduced expression is observed in a proportion of NMIBCs, and the 713 
majority of MIBCs demonstrate either reduced expression or a complete absence of E-cadherin; b) P-cadherin is 714 
expressed in the basal 1-2 layers of normal urothelium, and this pattern is preserved in the majority of NMIBCs. The 715 
majority of MIBCs demonstrate strong P-cadherin expression throughout the tumour mass; c) N-cadherin is not 716 
expressed in normal urothelium or the majority of NMIBCs. However, the majority of muscle-invasive UCs express N-717 
cadherin throughout the tumour mass.  718 
Figure 3: Proposed pathways for the development of a bladder cancer stem cell phenotype and the relationship 719 
with EpCAM (adapted from [23]). Cancer stem cells (CSCs) result in the development of treatment resistant disease 720 
in some cancer settings, and this diagram proposes potential pathways for their development in UBC. There is likely 721 
considerable plasticity in these pathways [142], with cells reverting to a less aggressive state by mesenchymal-to-722 
epithelial transition (MET) or by the reversal of the CSC phenotype, and most likely influenced by the tumour 723 
microenvironment [23]. We also propose a model whereby EpCAM modulates the development of EMT and/or CSCs 724 
(see text). 725 
Figure 4: EpCAM’s relationship with E-cadherin (adapted from [123;149]). The dual role of EPCAM in epithelial 726 
tissues is demonstrated. EpCAM can either disrupt the adherens junction, resulting in the release of β-catenin (a), or 727 
stabilise the adherens junction to maintain E-cadherin’s anchorage to the cell cytoskeleton (b). In (a), released β-728 
catenin subsequently forms a complex with EpICD and the transcriptional co-factor FHL2 [150], either at the cell 729 
membrane or in the cell nucleus. The EpICD/FHL2/β-catenin complex then interacts with the Lef-1 transcription 730 
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factor in the cell nucleus to activate the transcription of various target genes, including known oncogenes. In UBC we 731 
demonstrated that the extracellular domain of EpCAM is released by cleavage immediately adjacent to the cell 732 
membrane [52]. The exact location of cleavage was not described by Maetzel et al [123], but the protease involved 733 
(TACE or ADAM 17) usually cleaves membrane proteins 10-15 residues away from the membrane surface [127], 734 
suggesting atypical cleavage or an alternative mechanism of extracellular domain release in UBC. (α=α-catenin, β=β-735 
catenin). 736 
 737 
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Figure 1: Cell-cell adhesion in epithelial tissues.  739 
 740 
741 
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Figure 2: Cadherin switching in bladder UBCs.  742 
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Figure 3: Proposed pathways for the development of a bladder cancer stem cell phenotype and the relationship with EpCAM. 744 
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Figure 4: EpCAM’s relationship with E-cadherin.  747 
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